Dantrium (dantrolene), produced by Par Sterile Products, is a U.S. Food and Drug Administration (FDA) approved therapy for chronic spasticity (muscle spasms) from upper motor neuron disorders caused by MS and other conditions. The therapy induces skeletal muscle relaxation by affecting the contractile response.

Dantrium (dantrolene) is to be taken by mouth in weekly specified doses until benefit is observed.  Patients begin with 25 mg daily for seven days. They then take 25 mg three times a day for seven days, then 50 mg three times a day for seven days, followed by 100 mg three times a day (until a maximum dosage of 100 mg four times a day). In the event that no further benefit is observed at the next higher dose, dosage should be decreased to the previous dose.

The most common adverse effects reported were: muscle weakness, drowsiness, dizziness, fatigue, confusion, nervousness, nausea, thrombophlebitis, urticarial, erythema, and injection site reactions.

The therapy also includes a black box warning on the prescription drug label to call attention to serious or life-threatening risks. Dantrium may cause serious liver toxicity and symptomatic hepatitis (fatal or nonfatal) with different dosages. The risk of hepatic (liver) injury appears to be greater in women over age 35 who take higher dosages and other medications. Hepatic function should be monitored during therapy.

Dantrium is also available as a generic medicine.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

FDA Asked to Place Cannabis-based Therapy for Progressive MS on Fast Track, MMJ Holdings Says

A request for a potential cannabis-based treatment for multiple sclerosis to be given Fast Track designation, speeding its development as it readies to enter clinical testing, is now before the U.S. Food and Drug Administration (FDA), MMJ International Holdings announced. MMJ-001, as this lead candidate is known, aims to treat the spasticity (muscle stiffness) associated with progressive multiple sclerosis. The company is also targeting Huntington’s-associated chorea, […]

Direct Nerve Stimulation Using MyoRegulator System Seen to Reduce Spasticity in Mice with Spinal Injury

Treatment with PathMaker Neurosystems’ anodal trans‐spinal direct current stimulation (tsDCS), a non-invasive direct nerve stimulation tool called MyoRegulator, was found to effectively ease spasticity in mice with spinal cord injury, a study reports. A link between the ability to control muscle contraction and the levels of a specific neuronal transporter was also identified by its researchers, a […]

Controlling Spasticity Would Greatly Improve Everyday Quality of Life, Survey Shows

An international survey of caregivers and adults with neurological diseases, including multiple sclerosis (MS), revealed that spasticity is a hidden burden, having a negative effect on the ability to perform everyday tasks, and that relieving its symptoms significantly improves patients’ quality of life. The survey was presented by Ipsen, a global biopharmaceutical group, at the […]

MS News that Caught My Eye Last Week: Stimulator for Spasticity, Tysabri Dosing Trial, Mobility Devices Contest, Stem Cell Phase 2 Trial

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity I’m one of the many people with multiple sclerosis (MS) for whom spasticity is a significant problem. This is a nonmedicinal approach to dealing with it. I hope it doesn’t take too long to make this electrical stimulator available and, once it is, that […]

WeHealth, PathMaker Collaborating to Develop MyoRegulator as Noninvasive Treatment for Spasticity

WeHealth by Servier and PathMaker Neurosystems have established a new partnership to develop and commercialize the first neuromodulation technology for noninvasive treatment of spasticity, the companies announced. The agreement establishes an exclusive worldwide distribution arrangement, except for the U.S. and Japan, for PathMaker’s MyoRegulator. The MyoRegulator uses two pairs of disposable skin-surface electrodes that deliver synchronized stimulation […]

Cannabis-based Sublingual Tablet to Enter Trials in Israel as Possible Spasticity Treatment, OWCP Says

OWC Pharmaceutical Research is planning new clinical studies to evaluate the activity and safety of its cannabinoid-enriched sublingual soluble tablet. The company announced that an Institutional Review Board (IRB) in Israel approved its request to conduct a safety and tolerability trial there. The company also is asking to amend the study design, allowing the trial to […]

#ECTRIMS2018 — Data from 2 EU Trials Shows Effectiveness of Cannabidiol Spray in Treating Spasticity

Data from two European trials — a real-life study in Italy, and a long-term Czech trial looking at impact on cognition — supported the efficacy of a widely approved cannabinoid spray in treating moderate to severe spasticity (muscular stiffness or involuntary spasms) in multiple sclerosis (MS) patients who failed to benefit from other spasticity treatments. […]

Spasticity Scales May Not Be Sufficiently Informative of Sativex Benefits in MS Patients, Small Study Suggests

Spasticity scales may be insufficient to reflect the actual benefits of Sativex (nabiximols) treatment on spasticity symptoms in people with multiple sclerosis (MS), according to a small case series study. The results support the need to conduct a more extensive and functional examination to clarify treatment responses and help optimize treatment decisions. The study, “Variability […]

Using Medical Marijuana for MS Symptoms May Affect Your Employment

Ohio, my home state, is wrestling with the nuances of medical marijuana laws that become effective on Sept. 8, 2018. My husband’s work email had an important notice from the Bureau of Worker’s Compensation (BWC) about this pending change, and as I read it, I thought that nothing really changed. Although medical marijuana legalization has […]